Drug Combination Details
| General Information of the Combination (ID: C70019) | |||||
|---|---|---|---|---|---|
| Name | Danthron NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Experimental
Result(s) |
Danthron has an anticancer effect and can sensitize the chemotherapeutic effect of doxorubicin on pancreatic cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. Toxicol In Vitro. 2019 Feb;54:345-353. | |||
